Each year, seasonal influenza affects millions worldwide, leading to significant health burdens and economic costs. While vaccines remain the cornerstone of prevention, their efficacy can vary widely depending on the match between circulating strains and the vaccine formulation. Enter Flu Cedara Therapeutics , a biotech innovator that’s taking a bold new approach with CD388 , a first-in-class Drug-Fc Conjugate (DFC) designed for once-per-season flu prevention . What Makes CD388 Different? CD388 represents a paradigm shift in antiviral prophylaxis. Unlike traditional antivirals or vaccines, CD388 tethers a potent neuraminidase inhibitor to an Fc domain —a component of human antibodies. This unique design dramatically extends the drug’s half-life , allowing for sustained therapeutic levels throughout the entire flu season with just a single dose . Even more compelling is CD388’s immune-independent mechanism . Because it doesn’t rely on the host’s immune response, it holds particular pr...